Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study

AIMS: To describe the characteristics of patients receiving evolocumab in clinical practice across 12 European countries and simulate the association between low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular (CV) risk reduction. METHODS AND RESULTS: The characteristics of hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Kausik K, Dhalwani, Nafeesa, Sibartie, Mahendra, Bridges, Ian, Ebenbichler, Christoph, Perrone-Filardi, Pasquale, Villa, Guillermo, Vogt, Anja, Bruckert, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170569/
https://www.ncbi.nlm.nih.gov/pubmed/35175350
http://dx.doi.org/10.1093/ehjqcco/qcac009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170569/
https://www.ncbi.nlm.nih.gov/pubmed/35175350
http://dx.doi.org/10.1093/ehjqcco/qcac009

Ejemplares similares